M. Heinrich

Gastroenterology · 2000–2011

A researcher in the Science corpus: 19 papers; trusts 6 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Gastroenterology — 82 citations into it; #39 of 63 by trust here, #3 by citations
• Hematology — 57 citations into it
• Surgery — 39 citations into it

Whom M. Heinrich trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Christopher Corless
2. Heikki Joensuu
3. M. Miettinen
4. Brian J. Druker
5. D. Tuveson

Who trusts M. Heinrich overall

1. Christopher Corless
2. Heikki Joensuu
3. Z. Du
4. T. Yuan
5. M. Miettinen
6. Brian J. Druker
7. Robert B. West
8. Christine Lovly
9. Lewis C. Cantley

Papers from M. Heinrich's perspective

Ordered by how strongly the researchers M. Heinrich trusts endorse each paper. Same corpus, a different order for every researcher.

1. Diagnosis of gastrointestinal stromal tumors: A consensus approach. (Human Pathology)
2. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine)
3. Clinical management of gastrointestinal stromal tumors: before and after STI-571. (Human Pathology)
4. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* (Journal of Biological Chemistry)
5. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (Journal of Clinical Oncology)
6. Denaturing high‐performance liquid chromatography: A review (Human Mutation)
7. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. (Blood)
8. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. (Cancer Research)
9. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (The Journal of the National Comprehensive Cancer Network)
10. Genes expressed in human tumor endothelium. (Science)

Their papers

• Gastrointestinal stromal tumours: origin and molecular oncology (2011) — 852 citations
• KIT Gene Mutations and Copy Number in Melanoma Subtypes (2008) — 640 citations
• Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (2008) — 1,004 citations
• Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. (2008) — 728 citations
• Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. (2008) — 988 citations
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. (2006) — 2,477 citations
• Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. (2006) — 805 citations
• PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. (2005) — 865 citations
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. (2005) — 1,099 citations
• Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005) — 775 citations
• Biology of gastrointestinal stromal tumors. (2004) — 1,198 citations
• The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. (2004) — 656 citations
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. (2003) — 879 citations
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003) — 2,423 citations
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (2003) — 2,287 citations
• Clinical management of gastrointestinal stromal tumors: before and after STI-571. (2002) — 658 citations
• Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. (2002) — 672 citations
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002) — 4,306 citations
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. (2000) — 1,079 citations